Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: Results of a 2-year placebo-controlled study

BJU International

Volumn 97, Issue 4, 2006, Pages 734-741

  Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

1 blocker; Acute urinary retention; BPH; LUTS; Prolonged release alfuzosin; Surgery

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FLOW RATE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; POSITIONAL DIZZINESS; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SYNCOPE; URINE FLOW RATE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUINAZOLINES; RISK FACTORS; TREATMENT OUTCOME; URINARY RETENTION;

EID: 33644828388     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06110.x     Document Type: Article

References (18)

1. Girman CJ Jacobsen SJ Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries Urology 1998 51 428 36
2. Emberton M Andriole GL de la Rosette J et al. Benign prostatic hyperplasia: a progressive disease of aging men Urology 2003 61 267 73
3. Pickard R Emberton M Neal DE The management of men with acute urinary retention. National Prostatectomy Audit Steering Group Br J Urol 1998 81 712 20
4. Jacobsen SJ Jacobson DJ Rhodes T et al. Natural history of prostatism: risk factors for acute urinary retention J Urol 1997 158 481 7
5. Meigs JB Barry MJ Giovannucci E Rimm EB Stampfer MJ Kawachi I Incidence rates and risk factors for acute urinary retention: the health professionals follow-up study J Urol 1999 162 376 82
6. Fitzpatrick JM The natural history of BPH BJU Int 2006 97 in press
7. Roehrborn CG McConnell JD Lieber M et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia Urology 1999 53 473 80
8. Roehrborn C Definition of at-risk patients: baseline variable BJU Int 2006 97 in press
9. McConnell JD Roehrborn CG Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on clinical progression of benign prostatic hyperplasia N Engl J Med 2003 349 2387 98
10. van Kerrebroeck P Jardin A Laval KU van Cangh P Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group Eur Urol 2000 37 306 13
11. Roehrborn CG Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial Urology 2001 58 953 9
12. Roehrborn CG van Kerrebroeck P Nordling J Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies BJU Int 2003 92 257 61
13. Nordling J Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia BJU Int 2005 95 1006 12
14. Emberton M et al. Definition of at-risk patients: dynamic variables BJU Int 2006 97 in press
15. Roehrborn CG Kaplan SA Lee MW et al. Baseline post-void residual urine volume as a predictor of urinary outcomes in men with BPH in the MTOPS study J Urol 2005 173 Suppl. 443 A1638
16. van Kerrebroeck P Jardin A van Cangh P Laval KU ALFORTI Study Group. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study Eur Urol 2002 41 54 61
17. Elhilali M Emberton M Matzkin H et al. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in real-life practice BJU Int 2006 97 513 9
18. Hartung R Matzkin H Alcaraza et al. Age, comorbidity and hypertensive comedication do not affect cardiovascular tolerability of alfuzosin 10 mg once daily J Urol 2006 175 624 8